13F Holdings
中文EN

ENVB Enveric Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$2.78M$2.84M$7.25M$8.03M$4.79M
SG&A expense$5.79M$6.45M$8.85M$11.61M$20.50M
Operating income-$8.77M-$9.63M-$16.45M-$27.42M-$64.62M
Interest expense———$5,249$10,316
Pretax income-$8.77M-$9.57M-$17.26M-$19.96M-$56.43M
Income tax—$8,930$28,913-$1.49M-$7.45M
Net income-$8.77M-$9.57M-$17.29M-$18.47M-$48.98M
EBITDA-$8.57M-$9.29M-$16.10M-$27.09M-$63.97M
EPS (basic)-36.24-228.48-121.29-13.00-103.69
EPS (diluted)-36.24-228.48-121.29-13.00-2.07
Weighted avg. shares (diluted)334,71941,908143,9381.45M23.62M
Banking
Net interest income-$106$219$3,708-$5,249—
Balance sheet
Cash & equivalents$4.68M$2.24M$2.29M$17.72M$17.36M
Current assets$4.94M$2.73M$3.58M$18.43M$17.74M
PP&E, net$159,234$305,777$507,377$677,485$294,430
Goodwill———$379,686$1.59M
Intangibles—$42,182$210,932$379,686$548,436
Total assets$5.10M$3.08M$4.30M$19.55M$26.72M
Current liabilities$918,400$1.49M$2.34M$4.00M$2.74M
Total liabilities$918,400$1.49M$2.34M$4.00M$4.41M
Shareholders' equity$4.18M$1.59M$1.96M$14.67M$22.31M
Shares outstanding1.06M56,501182,6252.08M651,921
Cash flow statement
Operating cash flow-$8.14M-$7.73M-$14.09M-$17.15M-$11.46M
Capital expenditure——$5,180$584,165$189,719
Free cash flow——-$14.10M-$17.73M-$11.65M
Investing cash flow——$11,667-$584,165$2.19M
Financing cash flow$10.58M$7.67M-$1.34M$18.18M$24.90M
Depreciation & amortization$200,858$337,489$343,982$327,910$656,643
Stock-based compensation$827,323$1.56M$2.15M$2.62M$12.60M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.